Showing 8081-8090 of 10579 results for "".
- From EADV: Rezpegaldesleukin Effective Through 24 Weeks in REZOLVE-AD Trialhttps://practicaldermatology.com/news/from-eadv-rezpegaldesleukin-effective-through-24-weeks-in-rezolve-ad-trial/2483465/New data from the REZOLVE-AD presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress demonstrated that investigational IL-2 pathway agonist rezpegaldesleukin sustained effect beyond the 16-week induction period in patients with moderat
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://practicaldermatology.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate
- ZORYVE Wins 2025 Allure Best of Beauty Breakthrough Awardhttps://practicaldermatology.com/news/zoryve-wins-2025-allure-best-of-beauty-breakthrough-award/2483410/Arcutis Biotherapeutics’ ZORYVE® (roflumilast) was the recipient of Allure magazine’s 2025 Best of Beauty Breakthrough Award, marking the first time a prescription topical for atopic dermatitis (AD), plaque psoriasis, and seborrheic dermatitis has received the accol
- FDA Clears IND for Rubedo’s GPX4 Modulator in Actinic Keratosishttps://practicaldermatology.com/news/fda-clears-ind-for-rubedos-gpx4-modulator-in-actinic-keratosis/2483388/Rubedo Life Sciences has received FDA clearance for a second Investigational New Drug (IND) application for its lead compound RLS-1496, enabling a Phase 1b/2a trial in patients with actinic keratosis to begin in Q4 2025. Accordi
- Analysis: IL-17, JAK Inhibitors May Carry Elevated Risk for TBhttps://practicaldermatology.com/news/analysis-il-17-jak-inhibitors-may-carry-elevated-risk-for-tb/2483387/A large population-based analysis using data from TriNetX suggests a elevated risk of active tuberculosis (TB) in patients treated with systemic immunosuppressive therapies (including IL-17, IL-23, IL-12/23, Janus kinase (JAK) inhibitors), cyclosporine, and tumor ne
- LEO To Focus on New Data for CHE, AD, and PsO at EADV 2025https://practicaldermatology.com/news/leo-to-present-data-on-che-ad-and-pso-at-eadv-2025/2483384/LEO Pharma has unveiled its largest-ever scientific program for presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, chronic hand eczema (CHE), atopic dermatitis (AD), and plaque psoriasis, along with updates on investigational a
- Low Recurrence Observed in MIS Cases With Clear Biopsy Marginshttps://practicaldermatology.com/news/low-recurrence-observed-in-mis-cases-with-clear-biopsy-margins/2483319/A new retrospective cohort study suggests that diagnostic excisional biopsy alone maya be efficacious for select cases of melanoma in situ (MIS) that are neither lentigo maligna (LM) nor acral lentiginous melanoma (ALM) subtypes.
- IL-17 Inhibitors Not Linked to MACE: Analysishttps://practicaldermatology.com/news/il-17-inhibitors-not-linked-to-maces/2483300/Results from a large French case–time–control study revealed no association between the administration of interleukin (IL)-17 receptor A inhibitors and major adverse cardiovascular events (MACE). Researchers used data from mo
- Analysis Links NHR With Increased Risk of PsOhttps://practicaldermatology.com/news/analysis-links-nhr-with-increased-risk-of-pso/2483261/The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) is independently associated with an increased risk of psoriasis, raising the possibility of a novel biomarker for risk stratification, according to a large cross-sectional analysis of US adults published in Frontiers in Immuno
- Recall of DermaRite Industries Products Expandshttps://practicaldermatology.com/news/recall-of-dermarite-sanitizers-and-cleansers-expands/2483166/Citing an abundance of caution, DermaRite Industries has announced it is expanding its voluntary recall of hand sanitizers and cleansers initiated on